Efficacy of short‑term intensive treatment with insulin pump to improve islet β‑cell function in newly diagnosed type 2 diabetes via inhibition of oxidative stress

Abstract

The present study (Chinese Trial Registry GTB7027) assessed the effects of short-term intensive treatment with insulin pump on islet cell function in patients with newly diagnosed type 2 diabetes and the possible mechanism. A total of 100 patients newly diagnosed with type 2 diabetes and hospitalized between January 2016 and December 2017 were divided into a control and an experimental group (n=50 in each group). The subjects of the control group were administered multiple insulin injections for intensive treatment, while the experimental group received short-term intensive treatment with an insulin pump. Analysis of blood parameters, including lipids and glucose, as well as islet β-cell function were performed. The level of reactive oxygen species (ROS) in the peripheral blood mononuclear cells (PBMCs) from the patients was also measured. Oxidative stress indicators, including serum malondialdehyde (MDA) and superoxide dismutase (SOD), were also examined to explore the possible mechanism. The mRNA expression of heme oxygenase 1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) in PBMCs were analyzed by reverse transcription-quantitative PCR. The results indicated that the blood lipid levels were significantly improved in the two groups at two weeks, while the experimental group had significantly lower levels of total cholesterol and triglyceride, as well as low-and high-density lipoprotein cholesterol. The function of islet β-cells was significantly improved in the two groups. The insulin secretion index [homeostasis model assessment (HOMA) of β-cell function] in the experimental group was higher, while the insulin resistance (IR) index (HOMA of IR) was significantly lower than that in the control group. The serum MDA level in the experimental group was significantly lower and the SOD level was significantly higher compared with that in the control group. Following treatment, the level of ROS in diabetic PBMCs was significantly reduced, and the transcription level of HO-1 and Nrf2 were also significantly reduced (P<0.05). These results demonstrated that short-term intensive treatment with an insulin pump significantly improved lipid and blood glucose metabolism to protect islet function as well as significantly reducing the level of oxidative stress in patients with newly diagnosed type 2 diabetes.

The Effect of Two Different Doses of Astaxanthin on Alveolar Bone Loss in an Experimental Model of Periodontitis in Diabetic Rats

“…11 Several experimental and clinical trials have shown increased ROS in DM. [12][13][14][15] Receptor activator of nuclear factor-κB ligand (RANKL) is a type II homotrimeric transmembrane protein that is expressed in various cells, including osteoblasts, periodontal ligament (PL) cells, lymphocytes, and osteocytes. 16 Its main role in bone is the stimulation of osteoclast differentiation, activity, and inhibition of osteoclast apoptosis.…”

Estudo sobre a expressão de genes/proteínas chaves com papel no estresse oxidativo, inflamação e reparo do DNA em células mononucleares de pacientes com diabetes mellitus do tipo 2

“…Ressalta-se que poucos estudos avaliaram as isoformas da proteína SOD (SOD1 e SOD2) no DM2 (Mozzini et al, 2015;El-Gharbawy et al, 2016;Grindel et al, 2016;Sindhu et al, 2018;Sireesh et al, 2018;Liu et al, 2019) tal como foi realizado neste estudo. Ambas as isoformas de SOD estão localizadas em regiões celulares diferentes; enquanto a SOD1 está presente no citosol da célula, a SOD2 se localiza especificamente no interior da mitocôndria, uma organela amplamente afetada pelo DM2, o que ressalta a necessidade de SOD1 e SOD2 serem avaliadas de forma distinta.…”